Abstract
目的评价亲缘半相合造血干细胞移植(Haplo-HSCT)治疗重型再生障碍性贫血(SAA)的疗效,并且与同期进行的无关供者造血干细胞移植(UD-HSCT)进行比较。方法回顾性分析2012年9月至2014年7月接受替代供者造血干细胞移植的50例SAA患者临床资料;其中24例接受Haplo-HSCT, 26例接受UD-HSCT。结果中位随访时间9(2~26)个月,总生存(OS)率为91.3%。UD-HSCT组和Haplo-HSCT组OS率分别为96.1%和86.0%(P=0.30)。3例(6%)患者原发植入失败。Haplo-HSCT组患者Ⅱ~Ⅳ度急性移植物抗宿主病、慢性移植物抗宿主病、CMV血症、EBV血症发生率分别为37.5%、37.5%、78.2%及43.1%,均明显高于UD-HSCT组(3.83%、15.3%、46.1%及16.0%)(P值分别为0.003、0.030、0.005、0.040);出血性膀胱炎发生率差异无统计学意义(39.1%对23.0%,P=0.120)。结论Haplo-HSCT治疗SAA OS率较高,疗效与UD-HSCT相近。
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.